Publications by authors named "Sarah Schlotter"
Epstein-Barr virus (EBV) is a ubiquitous herpes virus associated with various cancers. EBV establishes latency with life-long persistence in memory B-cells and can reactivate lytic infection placing immunocompromised individuals at risk for EBV-driven lymphoproliferative disorders (EBV-LPD). Despite the ubiquity of EBV, only a small percentage of immunocompromised patients (~20%) develop EBV-LPD.
View Article and Find Full Text PDFArticle Synopsis
- This study compares immune system recovery in HIV-positive and HIV-negative patients after undergoing autologous hematopoietic cell transplant (AHCT) for lymphoma, evaluating their immune responses at multiple time points.
- Principal component analysis revealed that both groups showed distinct immune cell compositions compared to healthy controls, but their profiles improved over time, indicating a trend towards normalcy.
- Key findings include that HIV-positive recipients had higher levels of certain activated T cells but lower counts of B cells and natural killer (NK) cells, suggesting specific immune challenges that could inform treatment strategies for these patients.
Epstein-Barr virus (EBV) is a human herpes virus that infects over 90% of the world's population and is linked to development of cancer. In immune-competent individuals, EBV infection is mitigated by a highly efficient virus-specific memory T-cell response. Risk of EBV-driven cancers increases with immune suppression (IS).
View Article and Find Full Text PDFNon-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers arising in lymphoid tissues that commonly effects both humans and dogs. Protein arginine methyltransferase 5 (PRMT5), an enzyme that catalyzes the symmetric di-methylation of arginine residues, is frequently overexpressed and dysregulated in both human solid and hematologic malignancies. In human lymphoma, PRMT5 is a known driver of malignant transformation and oncogenesis, however, the expression and role of PRMT5 in canine lymphoma has not been explored.
View Article and Find Full Text PDFArticle Synopsis
- Multiple myeloma is largely incurable, with most patients facing high mortality rates within five years after diagnosis, prompting the search for effective therapies.
- Reolysin, a viral oncolytic therapy derived from human reovirus, shows promise in targeting multiple myeloma cells, but previous trials revealed limited efficacy as the virus did not replicate significantly within these cells.
- Research indicates that enhancing the expression of the viral receptor JAM-1 through histone deacetylase inhibitors (HDACi) can improve the effectiveness of Reolysin, suggesting a potential combined therapeutic strategy for better treatment outcomes in multiple myeloma.